PeproMene Bio Shows Promising Progress with PMB-CT01
IRVINE, Calif. — PeproMene Bio, Inc., a notable clinical-stage biotechnology firm focused on advancements in treatment for relapsed and refractory B-cell malignancies, has achieved a significant milestone. Two abstracts from the ongoing Phase 1 trials of PMB-CT01, a BAFFR-CAR T therapy, have been accepted for oral presentations at a prestigious annual meeting.
Key Findings on PMB-CT01
The abstracts present valuable insights into the safety and efficacy of PMB-CT01, particularly among patients with heavily pretreated relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma (B-NHL). These findings highlight PMB-CT01's effectiveness in patients who either did not respond to prior CD19 therapies or have CD19-negative disease, revealing a differentiated target that could overcome CD19 antigen escape. The interim results from the Phase 1 dose-escalation studies show promising safety profiles alongside effective results.
Insights on r/r B-NHL
Safety Profile: The PMB-CT01 therapy demonstrated a remarkable tolerability with no cases of Grade >1 Cytokine Release Syndrome (CRS) and no Grade >1 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) reported.
Efficacy: All seven initial patients experienced a Complete Response (CR) within 1 to 3 months following the infusion, including those who had undergone previous CD19-directed therapies and those with CD19-negative status.
Durability of Response: The patients' remissions have continued for over 32 months, with a median duration of 17 months as confirmed during data analysis.
Highlights of r/r B-ALL
Efficacy: Among six patients enrolled, four achieved an undetectable Minimal Residual Disease (MRD-) CR, a notable accomplishment in this high-risk population.
High-Risk Achievements: Three of the four responders were CD19-negative at the start of the trial and successfully proceeded to allogeneic hematopoietic cell transplant with curative intent.
Safety Measures: No Dose-Limiting Toxicities (DLTs) were found during the study, with only one patient experiencing Grade 2 CRS while there were no reports of Grade 3 CRS.
The Future of B-cell Malignancy Treatments
Dr. Hazel Cheng, COO of PeproMene Bio, expressed optimism regarding the data. She stated, "The consistent and durable performance across both types of B-cell malignancies, especially in patients with exhausted CD19 options, underscores BAFF-R's potential as a safe and highly effective therapeutic alternative. This data emphasizes the capability of PMB-CT01 to meet critical unmet medical needs in high-risk relapsed disease scenarios."
Details of the ASH 2025 Presentations
PeproMene Bio will present two abstracts at the ASH 2025 Annual Meeting:
- Abstract Title: BAFFR-CAR T cells demonstrate durable responses and manageable toxicities in r/r B-cell lymphomas…
Abstract Reference: abs25-7079
Date/Time: December 6, 2:45 PM
Presenter: Elizabeth Budde, M.D., Ph.D. - Abstract Title: BAFFR-CAR T cells show promising safety and anti-leukemia efficacy in r/r B-cell ALL patients…
Abstract Reference: abs25-2035
Date/Time: December 8, 11:00 AM
Presenter: Ibrahim Aldoss, M.D.
About PMB-CT01 Therapy
PMB-CT01 stands out as a pioneering BAFF-R–targeted autologous CAR T cell therapy, primarily targeting B cells essential for survival. This therapy aims to limit the chance of antigen-loss escape while being thoroughly investigated in its Phase 1 trials aimed at treating r/r B-NHL and r/r B-ALL.
Frequently Asked Questions
What is PMB-CT01?
PMB-CT01 is an innovative CAR T cell therapy targeted at BAFF-R, which is crucial for the survival of B cells.
What conditions does PMB-CT01 aim to address?
PMB-CT01 focuses on treating relapsed and refractory B-cell malignancies, particularly B-ALL and B-NHL.
What were the outcomes presented at the ASH 2025 Meeting?
The outcomes highlighted the safety, efficacy, and durability of responses in patients treated with PMB-CT01.
Who will present the abstracts at ASH 2025?
Elizabeth Budde and Ibrahim Aldoss, both notable doctors in their fields, will present at the conference.
What does the future hold for B-cell malignancy therapies?
The continued development of therapies like PMB-CT01 holds significant promise for improving outcomes in B-cell malignancies, particularly in high-risk patients.